Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815340 | 0.84 | KMT2A (0.45) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL16815804 | 0.82 | L3MBTL1 (0.43) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL16815728 | 0.81 | KMT2A (0.46) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL16815528 | 0.81 | L3MBTL1 (0.42) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL22725615 | 0.79 | CHRNA7 (0.35) | LOXL2LOXPOLB | |
| SCHEMBL16815578 | 0.79 | L3MBTL1 (0.41) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL16815720 | 0.78 | KMT2A (0.41) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL16815360 | 0.78 | KMT2A (0.44) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL20971432 | 0.78 | SMN1; SMN2 (0.43) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL16815416 | 0.77 | HTR7 (0.51) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809358-B2 | Use of IκB-kinase inhibitors in pain therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8778955-B2 | Indole derivatives or benzimidazole derivatives for modulating IkB kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| EP-2233483-B1 | Indole or Benzimidazole derivatives as IkB-kinase modulators and intermediates in their preparation. | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-05-09 | — | — | EP | disclosed |
| EP-1530568-B1 | INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-29 | — | — | EP | disclosed |
| EP-2233483-A1 | Indole or Benzimidazole derivatives as IkB-kinase modulators and intermediates in their preparation. | Sanofi-Aventis Deutschland GmbH (DE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090069358-A1 | Use of IKappaB-Kinase Inhibitors in Pain Therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1531819-B1 | USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-12-24 | — | — | EP | disclosed |
| US-7462638-B2 | Use of IκB-kinase inhibitors in pain therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7307088-B2 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-7285560-B2 | Indole derivatives or benzimidazole derivatives for modulating IκB kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-23 | — | — | US | disclosed |
| US-20070244139-A1 | Indole Derivatives or Benzimidazole Derivatives for Modulating IkB Kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20050197353-A1 | Indole derivatives or benzimidazole derivatives for modulating IkB kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| EP-1531819-A1 | USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN | Aventis Pharma Deutschland GmbH (DE) | 2005-05-25 | — | — | EP | disclosed |
| EP-1530568-A1 | INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE | Aventis Pharma Deutschland GmbH (DE) | 2005-05-18 | — | — | EP | disclosed |
| EP-1519921-A2 | SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040116494-A1 | Use of IkappaB-kinase inhibitors in pain therapy | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | US | disclosed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| WO-2004022057-A1 | USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022553-A1 | INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IκB KINASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004005279-A2 | SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244139-A1 | Indole Derivatives or Benzimidazole Derivatives for Modulating IkB Kinase | IKBKB, IKBKG, IKBKE | L3MBTL1 1780/4885SMN1; SMN2 3861/4885KMT2A 1433/4885 |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | L3MBTL1 3094/4885SMN1; SMN2 3639/4885KMT2A 1930/4885 |
| US-20090069358-A1 | Use of IKappaB-Kinase Inhibitors in Pain Therapy | NFKBIA, IKBKB, IKBKE | L3MBTL1 2334/4885SMN1; SMN2 2986/4885KMT2A 2729/4885 |
| US-20050197353-A1 | Indole derivatives or benzimidazole derivatives for modulating IkB kinase | IKBKB, IKBKG, IKBKE | L3MBTL1 1780/4885SMN1; SMN2 3861/4885KMT2A 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.